Therapeutic perspectives for adult soft tissue sarcoma—updates from the 2022 ASCO annual meeting

查看全文 作　　者：Jilong [1]Yang;Yu [2]Xu;Yong [2]Chen;Tao [3]Li;Xiaowei [4]Zhang;Tu [2]Hu;Ruwei [1]Xing;Yun [1]Yang

机构地区：[1]Department of Bone and Soft Tissue Tumor,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin’s Clinical Research Center for Cancer,Key Laboratory of Molecular Cancer Epidemiology,Tianjin 300060,China;[2]Department of Musculoskeletal Surgery,Fudan University Shanghai Cancer Center,Fudan University,Shanghai 200032,China;[3]Department of Bone and Soft tissue Surgery,Zhejiang Cancer Hospital,Hangzhou 310022,China;[4]Department of Gastrointestinal Medical Oncology,Fudan University Shanghai Cancer Center and Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China

出　　处：《Cancer Biology & Medicine》索引2022年第19卷第10期,共7页

摘　　要：At the recent 2022 American Society of Clinical Oncology(ASCO)annual meeting,the latest progress was presented in clinical trials of various therapeutic modalities for adult soft tissue sarcoma(STS),including chemotherapy,targeted therapy,anti-immune checkpoint immunotherapy,and multiple combination treatments(Table 1).Generally,the development of clinical treatments for STS is relatively slow,owing to the complex pathological subtypes of sarcoma and their heterogeneous biological behaviors.Here,we briefly summarize updates from this year’s ASCO meeting and discuss the future therapeutic perspectives for unspecific STS. 关键词：ASCO CHEMOTHERAPY treatment

相关文献

参考文献（29）
引证文献（2）
耦合文献（0）

参考文献(29)

引证文献(2)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Therapeutic perspectives for adult soft tissue sarcoma—updates from the 2022 ASCO annual meeting

参考文献(29)

引证文献(2)

用户提示